Cardiomyocytes in Persistent Cancer Therapy-related Cardiac Dysfunction Show Contractile and Natriuretic Peptide Signaling Signatures

BACKGROUND. Anthracycline and trastuzumab therapy of HER2-positive breast cancer causes cancer therapy-related cardiac dysfunction (CTRCD) in a subset of treated patients. Some recover cardiac function, others do not. Whether persistence is a cardiomyocyte-intrinsic property is unknown. OBJECTIVES. We sought to determine whether induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from patients with persistent CTRCD respond to these drugs differently from those of patients with reversible or no CTRCD, and to identify the functional pathways involved. METHODS. iPSCs were derived from 23 women with normal baseline cardiac function treated with doxorubicin-based chemotherapy followed by trastuzumab: 5, 11 and 7 with no, reversible, and persistent CTRCD, respectively. iPSC-CMs were exposed to 7 drug regimens, generating 161 transcriptomic profiles that we resolved by singular value decomposition and subjected to pathway enrichment analysis. Reliability was tested by 100 clinical label permutations and leave-one-patient-out downsampling. RESULTS. Persistent CTRCD responses clustered more tightly and separated from reversible and no-CTRCD responses to a higher degree than expected by chance (P = 0.04). Reversible and no-CTRCD responses did not resolve from one another. Genes encoding guideline-recommended biomarkers, including natriuretic peptides and cardiac troponins, were more strongly induced or less repressed in persistent CTRCD cell lines, while natriuretic peptide receptor signaling was lower. Contraction, calcium handling, cytoskeletal and glycolytic pathways differed between CTRCD groups. Comparison with signatures induced by cardiotoxic kinase inhibitors in healthy donor cardiomyocytes documented high functional similarities. CONCLUSIONS. Cardiomyocytes display a cell-intrinsic signature of persistent CTRCD that centers on contractile homeostasis and natriuretic peptide receptor signaling, supporting patient group-selective cardioprotective intervention strategies.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.13.766492
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Cardiomyocytes in Persistent Cancer Therapy-related Cardiac Dysfunction Show Contractile and Natriuretic Peptide Signaling Signatures

Ravi Iyengar, Angel T. Chan, Jens Hansen
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Chemotherapy-induced cardiotoxicity and mitigation
preprint

Cardiomyocytes in Persistent Cancer Therapy-related Cardiac Dysfunction Show Contractile and Natriuretic Peptide Signaling Signatures

Ravi Iyengar, Angel T. Chan, Jens Hansen
preprint en

Abstract

BACKGROUND. Anthracycline and trastuzumab therapy of HER2-positive breast cancer causes cancer therapy-related cardiac dysfunction (CTRCD) in a subset of treated patients. Some recover cardiac function, others do not. Whether persistence is a cardiomyocyte-intrinsic property is unknown. OBJECTIVES. We sought to determine whether induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from patients with persistent CTRCD respond to these drugs differently from those of patients with reversible or no CTRCD, and to identify the functional pathways involved. METHODS. iPSCs were derived from 23 women with normal baseline cardiac function treated with doxorubicin-based chemotherapy followed by trastuzumab: 5, 11 and 7 with no, reversible, and persistent CTRCD, respectively. iPSC-CMs were exposed to 7 drug regimens, generating 161 transcriptomic profiles that we resolved by singular value decomposition and subjected to pathway enrichment analysis. Reliability was tested by 100 clinical label permutations and leave-one-patient-out downsampling. RESULTS. Persistent CTRCD responses clustered more tightly and separated from reversible and no-CTRCD responses to a higher degree than expected by chance (P = 0.04). Reversible and no-CTRCD responses did not resolve from one another. Genes encoding guideline-recommended biomarkers, including natriuretic peptides and cardiac troponins, were more strongly induced or less repressed in persistent CTRCD cell lines, while natriuretic peptide receptor signaling was lower. Contraction, calcium handling, cytoskeletal and glycolytic pathways differed between CTRCD groups. Comparison with signatures induced by cardiotoxic kinase inhibitors in healthy donor cardiomyocytes documented high functional similarities. CONCLUSIONS. Cardiomyocytes display a cell-intrinsic signature of persistent CTRCD that centers on contractile homeostasis and natriuretic peptide receptor signaling, supporting patient group-selective cardioprotective intervention strategies.

bioRxiv (Cold Spring Harbor Laboratory)
Memorial Sloan Kettering Cancer Center (US), Icahn School of Medicine at Mount Sinai (US)
New York State Department of Health
Good health and well-being
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon